Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic Hyperplasia
- 1 July 1995
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 154 (1), 100-104
- https://doi.org/10.1016/s0022-5347(01)67239-2
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.JCI Insight, 1992
- Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In VivoSeminars in Thrombosis and Hemostasis, 1992
- Sex hormones, lipoproteins, and cardiovascular riskAtherosclerosis, 1991
- A Prospective Study of Cholesterol, Apolipoproteins, and the Risk of Myocardial InfarctionNew England Journal of Medicine, 1991
- Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in menAmerican Journal of Hematology, 1991
- Effects of androgenic steroids on erythropoiesisSteroids, 1985
- Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroidsMetabolism, 1984
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart diseaseJAMA, 1984
- Plasma Lipoproteins during Anti-Androgen Treatment by Estrogens or Orchidectomy in Men with Prostatic CarcinomaHormone and Metabolic Research, 1981
- ARE APOLIPOPROTEINS BETTER DISCRIMINATORS THAN LIPIDS FOR ATHEROSCLEROSIS?The Lancet, 1979